OptiMARK® is a formulation of a nonionic gadolinium chelate of diethylenetriamine pentaacetic acid bismethoxyethylamide (gadoversetamide), for use as a paramagnetic MRI contrast agent. OptiMARK® (gadoversetamide injection) is to be administered by intravenous injection. OptiMARK® is indicated for MRI diagnostic procedures to provide increased enhancement and visualization of lesions of the brain, spine and liver, including tumors.

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m²), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.

Short name: Gd-HP-DO3A, generic name: Gadoteridol injection, chemical compound: Gd-1,4,7-tris(carbonylmethyl)-10-(2'-hydroxypropyl)-1,4,7,10-tetraazacyclododecane
(ProHance®) A nonionic MRI contrast agent with a low molecular weight complex of gadolinium (macrocyclic chelate, which tightly binds the Gd atom).
Gadoteridol does not cross the blood brain barrier. If the barrier is damaged, gadoteridol will penetrate into lesions such as tumors. It also highlights areas of increased vascularity so it has been used to improve the delimitation of lesions elsewhere in the body.
Apart from its paramagnetic effects, gadoteridol has no pharmacological activity in the body. After intravenous injection, most of the dose is excreted unchanged in the urine within 24 hours.

See also Contrast Agents and ProHance®.